29 Oct Brand-Name Drug Company Allergan Agrees to Pay Record $750M to Settle Antitrust Claims Based on Alleged Hatch-Waxman Abuses
Settlement is largest for a single defendant in an antitrust case involving delayed market entry of generic drugs NEW YORK – A class of wholesale drug distributors has reached a record $750 million settlement resolving antitrust claims based on anticompetitive conduct related to the Alzheimer’s...